A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Niraparib (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms BEDIVERE
- Sponsors Janssen Research & Development
- 15 Feb 2020 Results evaluating safety and PK of niraparib plus androgen receptor-targeted therapy (ART) in patients with metastatic castration-resistant prostate cancer, presented at the 2020 Genitourinary Cancers Symposium
- 03 Feb 2020 According to a Janssen media release, data from this trial will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco.
- 26 Jul 2019 Status changed from active, no longer recruiting to completed.